JP Morgan Chase’s Matinas BioPharma MTNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-60
| Closed | -$470 | – | 7445 |
|
|
2025
Q1 | $470 | Hold |
60
| – | – | ﹤0.01% | 6709 |
|
|
2024
Q4 | $461 | Sell |
60
-1
| -2% | -$23 | ﹤0.01% | 6813 |
|
|
2024
Q3 | $3.23K | Hold |
61
| – | – | ﹤0.01% | 6557 |
|
|
2024
Q2 | $7.22K | Hold |
61
| – | – | ﹤0.01% | 6318 |
|
|
2024
Q1 | $12.3K | Hold |
61
| – | – | ﹤0.01% | 6313 |
|
|
2023
Q4 | $9.8K | Buy |
61
+1
| +2% | +$169 | ﹤0.01% | 6407 |
|
|
2023
Q3 | $5.88K | Hold |
60
| – | – | ﹤0.01% | 6350 |
|
|
2023
Q2 | $16.2K | Hold |
60
| – | – | ﹤0.01% | 5961 |
|
|
2023
Q1 | $21K | Hold |
60
| – | – | ﹤0.01% | 5963 |
|
|
2022
Q4 | $23K | Hold |
60
| – | – | ﹤0.01% | 5842 |
|
|
2022
Q3 | $29K | Hold |
60
| – | – | ﹤0.01% | 5704 |
|
|
2022
Q2 | $36K | Hold |
60
| – | – | ﹤0.01% | 5750 |
|
|
2022
Q1 | $36K | Hold |
60
| – | – | ﹤0.01% | 5906 |
|
|
2021
Q4 | $45K | Hold |
60
| – | – | ﹤0.01% | 5992 |
|
|
2021
Q3 | $59K | Sell |
60
-2
| -3% | -$1.29K | ﹤0.01% | 5780 |
|
|
2021
Q2 | $36K | Buy |
62
+2
| +3% | +$1.29K | ﹤0.01% | 5824 |
|
|
2021
Q1 | $47K | Hold |
60
| – | – | ﹤0.01% | 5544 |
|
|
2020
Q4 | $61K | Hold |
60
| – | – | ﹤0.01% | 5116 |
|
|
2020
Q3 | $35K | Hold |
60
| – | – | ﹤0.01% | 5036 |
|
|
2020
Q2 | $35K | Hold |
60
| – | – | ﹤0.01% | 4931 |
|
|
2020
Q1 | $27K | Hold |
60
| – | – | ﹤0.01% | 4881 |
|
|
2019
Q4 | $102K | Hold |
60
| – | – | ﹤0.01% | 4890 |
|
|
2019
Q3 | $28K | Hold |
60
| – | – | ﹤0.01% | 5334 |
|
|
2019
Q2 | $38K | Hold |
60
| – | – | ﹤0.01% | 5280 |
|
|
2019
Q1 | $49K | Hold |
60
| – | – | ﹤0.01% | 5144 |
|
|
2018
Q4 | $27K | Hold |
60
| – | – | ﹤0.01% | 5261 |
|
|
2018
Q3 | $41K | Hold |
60
| – | – | ﹤0.01% | 5266 |
|
|
2018
Q2 | $20K | Sell |
60
-18
| -23% | -$7.8K | ﹤0.01% | 5304 |
|
|
2018
Q1 | $44K | Sell |
78
-1
| -1% | -$793 | ﹤0.01% | 4863 |
|
|
2017
Q4 | $68K | Buy |
79
+19
| +32% | +$18.3K | ﹤0.01% | 4796 |
|
|
2017
Q3 | $59K | Hold |
60
| – | – | ﹤0.01% | 4433 |
|
|
2017
Q2 | $76K | Buy |
+60
| New | +$121K | ﹤0.01% | 4249 |
|
Other funds holding MTNB
JP Morgan Chase's MTNB Position: Q2 2025 in Review
JP Morgan Chase sold out of Matinas BioPharma (MTNB) in Q2 2025, closing a stake of 60 shares — an estimated $470 sold.
JP Morgan Chase first reported a position in MTNB in Q2 2017 and held it in 32 quarters. The position peaked at $102K in Q4 2019. 21 funds tracked by Wall St. Rank hold MTNB as of Q2 2025.
- JP Morgan Chase reported no remaining Matinas BioPharma position as of Q2 2025 after selling out during the quarter.
- JP Morgan Chase sold 60 Matinas BioPharma shares in Q2 2025, an estimated $470.
- JP Morgan Chase first reported a position in Matinas BioPharma in Q2 2017 and held it in 32 quarters.
- JP Morgan Chase's Matinas BioPharma position peaked at $102K in Q4 2019.
- 21 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2025.
Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.